LEGN · Legend Biotech Corporation
$22.22
-1.19% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
17.6
Dividend yield
—
Beta
0.34
Avg volume
3M
Employees
3K
2D change
—
5D change
-18.10%
10D change
-13.43%
30D change
-32.83%
60D change
-29.05%
MTD change
-35.53%
YTD change
-11.36%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LEGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
RBC Capital
Outperform$59.00
+165.5% vs priceUBS
Neutral$28.00
+26.0% vs priceMorgan Stanley
Overweight$48.00
+116.0% vs priceBarclays
Overweight$80.00
+260.0% vs priceJP Morgan
Overweight$76.00
+242.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | HC Wainwright & Co. | Reiterates | Buy | $65.00 |
| 2026-07-27 | RBC Capital | Maintains | Outperform | $63.00 → $59.00 |
| 2026-07-24 | UBS | Downgrade | Buy → Neutral | $49.00 → $28.00 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $64.00 → $63.00 |
| 2026-06-03 | UBS | Maintains | Buy | $31.00 → $49.00 |
| 2026-06-03 | HC Wainwright & Co. | Maintains | Buy | $50.00 → $65.00 |
| 2026-05-18 | HC Wainwright & Co. | Reiterates | Buy | $50.00 |
| 2026-05-13 | TD Cowen | Maintains | Hold | $21.00 → $29.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 24 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 33.4% below the 50-day MA ($28.57).
- Price vs 200-day MA: Trading 23.2% below the 200-day MA ($24.79).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.57) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.65) and high ($43.36).
LEGN Price Chart
Loading chart for LEGN…
Fundamentals
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.